Kate Farrell, PhD, is currently doing preclinical product development for the Novel Therapeutics division of Epistem, a UK-based biotechnology company focused on epithelial stem cell biology, with applications in the areas of oncology, gastrointestinal diseases and dermatology. She formerly worked in a variety of roles at Amgen until the end of 2007, the most recent being head of Global Clinical Supply Chain Management. Prior to this, she was the Oncology Therapeutic Area Head in Global Operations Planning. She also worked in Medical Affairs on a product launch, and was Product Team Leader during the transition of a pipeline product from Phase 2 to 3. Dr. Farrell initially joined Amgen in 1992 and worked 8 years as a research scientist in the preclinical division. She has a PhD in biophysics from the University of Western Ontario in London, ON, Canada, and was a Medical Research Council of Canada Post Doctoral Fellow initially at UCLA, and then at the Max Plank Institute in Munich, Germany. Her areas of research expertise include vascular biology as well as epithelial biology and gastrointestinal pathology.